APP Submits Abraxane NDA; Will Position As Safer, More Effective Than Taxol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
American Pharmaceutical Partners is describing its pending paclitaxel agent Abraxane as a safer, more convenient and more effective alternative to Bristol-Myers Squibb’s Taxol and generics.